LSD has a controversial and extraordinary reputation, due to the special effects it can induce on human consciousness.This book is the first ever comprehensive review of the psychological and pharmacological effects of LSD. It draws on data from more than 3000 experimental and clinical studies.

This volume is the proceedings of the Symposium of the Swiss Academy of Medical Sciences held in Lugano-Agno in Switzerland in September 1993. It includes chapters in pharmacological, psychopathological and clinical aspects of LSD and hallucinogenic drug use in medicine, in addition to a personal historical account of the discovery of LSD by Professor Albert Hofmann, as well as social and cultural aspects of LSD.

Between 1954 and 1962 Dr. Oscar Janiger administered LSD to more than 950 people from all walks of life. The data collected from those trials, and from follow-up studies 40 years later, is now available for the first time.

This handbook reviews promising applications of psychedelics in treatment of such challenging psychiatric problems as posttraumatic stress disorder, major depression, substance use disorders, and end-of-life anxiety. Experts from multiple disciplines synthesize current knowledge on psilocybin, MDMA, ketamine, and other medical hallucinogens. The volume comprehensively examines these substances' neurobiological mechanisms, clinical effects, therapeutic potential, risks, and anthropological and historical contexts. Coverage ranges from basic science to practical clinical considerations, including patient screening and selection, dosages and routes of administration, how psychedelic-assisted sessions are structured and conducted, and management of adverse reactions.

Carl Gustav Jung pioneered the transformative potential of the deep unconscious. Psychedelic substances provide direct and powerful access to this inner world. How, then, might Jungian psychology help us to better understand the nature of psychedelic experiences? And how might psychedelics assist the movement toward psychological transformation described by Jung? Jungian depth psychology and psychedelic psychotherapy are both concerned with coming to terms with unconscious drives, complexes, and symbolic images. Unaware of significant evidence for the safe clinical use of psychedelic drugs, Jung himself remained wary of psychedelics and staunchly opposed their therapeutic use. His bias has prevented Jungians from objectively considering the benefits as well as the risks of using psychedelics for psychological healing and growth. Confrontation with the Unconscious intertwines psychedelic research, personal accounts of psychedelic experiences, and C. G. Jung's work on trauma, the shadow, psychosis, and psychospiritual transformation - including Jung's own confrontation with the unconscious - to show the relevance of Jung's penetrating insights to the work of Stanislav Grof, Ann Shulgin, Ronald Sandison, Margot Cutner, among other psychedelic and transpersonal researchers, and to demonstrate the great value of Jung's penetrating insights for understanding difficult psychedelic experiences and promoting safe and effective psychedelic exploration and psychotherapy.

The rise—and fall—of research into the therapeutic potential of LSD. After LSD arrived in the United States in 1949, the drug's therapeutic promise quickly captured the interests of psychiatrists. In the decade that followed, modern psychopharmacology was born and research into the drug's perceptual and psychological effects boomed. By the early 1960s, psychiatrists focused on a particularly promising treatment known as psychedelic therapy: a single, carefully guided, high-dose LSD session coupled with brief but intensive psychotherapy. Researchers reported an astounding 50 percent success rate in treating chronic alcoholism, as well as substantial improvement in patients suffering from a range of other disorders. Yet despite this success, LSD officially remained an experimental drug only. Research into its effects, psychological and otherwise, dwindled before coming to a close in the 1970s. In The Trials of Psychedelic Therapy, Matthew Oram traces the early promise and eventual demise of LSD psychotherapy in the United States. While the common perception is that LSD's prohibition terminated legitimate research, Oram draws on files from the Food and Drug Administration and the personal papers of LSD researchers to reveal that the most significant issue was not the drug's illegality, but the persistent question of its efficacy. The landmark Kefauver-Harris Drug Amendments of 1962 installed strict standards for efficacy evaluation, which LSD researchers struggled to meet due to the unorthodox nature of their treatment. Exploring the complex interactions between clinical science, regulation, and therapeutics in American medicine, The Trials of Psychedelic Therapy explains how an age of empirical research and limited government oversight gave way to sophisticated controlled clinical trials and complex federal regulations. Analyzing the debates around how to understand and evaluate treatment efficacy, this book will appeal to anyone with an interest in LSD and psychedelics, as well as mental health professionals, regulators, and scholars of the history of psychiatry, psychotherapy, drug regulation, and pharmaceutical research and development.